Background: High Mobility Group Box 1 (HMGB-1) is a 30 kDa protein that is a lethal mediator in sepsis and is a recognized therapeutic target. However, no consensus has been reached for acute blood purification therapy as a treatment for sepsis targeting HMGB-1. Previous studies demonstrated that a high anti-HMGB-1 antibody titer and the suppression of HMGB-1 activity improved survival rate in animal sepsis models. The aim of this study was to evaluate whether plasma adsorption therapy is able to decrease the level of HMGB-1, representing a new potential treatment strategy against sepsis.
Introduction
Various mediators are known to play a role in sepsis and septic shock. In severe sepsis, pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), are recognized by pattern recognition receptors such as toll-like receptors (TLRs) and promote cytokine production 1, 2 . As a result of this inflammatory cascade, tissue and organ damage can occur. In addition to
PAMPs, alarmins like HMGB-1 have been found to bind to pattern recognition receptors causing inflammation 3, 4 .
That is, even if PAMPs are not present, alarmins can amplify inflammation. PAMPs and alarmins are collectively called damage-associated molecular patterns (DAMPs), and this biological reaction is called the damage chain reaction 5 .
In severe sepsis, it is extremely important to control DAMPs, including HMGB-1. The amount of HMGB-1 is significantly correlated with the disseminated intravascular coagulation (DIC) score and the sepsis-related organ failure assessment (SOFA) score 6 . HMGB-1 is a 30 kDa indispensable protein, which was discovered as a DNA binding protein and is a mediator of cell death when it circulates through the body 7 . It has also been identified as one of the lethal mediators at the late stage of sepsis There are treatment guidelines for sepsis and septic shock, such as the surviving sepsis campaign guidelines (SSCG) 13 and the Japanese guidelines for the management of sepsis 14 . However, acute blood purification therapy, such as polymyxin-B immobilized column direct hemoperfusion (PMX-DHP) and continuous hemodiafiltration (CHDF), has remained controversial as a treatment option for sepsis.
An aberrant activation of HMGB-1 in sepsis should be controlled and adsorption therapy has been reported to be one of the promising mechanisms to reduce these levels 15 . HMGB-1 is a 30 kDa protein, but existing filtration membranes are not capable of efficient removal of substances bigger than 20 kDa. Alternatively, plasma adsorption therapies using different columns have been clinically applied for various autoimmune diseases. However, these columns were never tested to reduce the HMGB-1 level in patients with sepsis.
Thus, the purpose of this study was to evaluate whether HMGB-1 can be efficiently adsorbed by columns that have been utilized for autoimmune diseases.
Materials and Methods

Tools and Devices
Plasma adsorption therapy is a treatment for various autoimmune diseases such as Myasthenia gravis, Guillain-Barre syndrome and Multiple sclerosis 16, 17 . It is also used to treat fulminant hepatitis and postoperative liver failure. In plasma adsorption therapy, blood is drawn and passed through a plasma separator. Then, the separated plasma is brought into contact with the adsorbed column to remove etiologic substances 18 
Experimental Procedure
FBS contains a significant amount of HMGB-1. Experiments were carried out using commercially available bovine serum purchased from SIGMA-ALDRICH, Tokyo, 
Statistical Analysis
All results are expressed as the mean values±standard deviations (SD). Differences in each value were analyzed by ONE-way ANOVA. All statistical analyses ware conducted using EZR (Saitama Medical Center of Jichi Medical University, Saitama, Japan) 22 . A p-value less than 0.05 was interpreted to be statistically significant.
Results
The highest adsorption of HMGB-1 was found in IM-TR, followed by BRS and IM-PH.
The actual concentrations of plasma HMGB-1 in each column are shown in In the IM-TR, the adsorption efficiency of HMGB-1 was approximately 90% initially, but gradually declined toward the end of the experiment. Although BRS showed relatively lower adsorption efficiency than that of IM-TR, it maintained a steady removal rate of HMGB-1 at 45% throughout the experiment. IM-PH had the lowest adsorption efficiency, which was less than 10%.
The total average removal rates at 75 minutes were 70.8% in the IM-TR, 44.5% in BRS, and 7.2% in the IM- Fig. 3 The High Mobility Group Box-1 (HMGB-1) removal rates of each column are shown at 25 minutes, 50 minutes, and 75 minutes after the injection. The HMGB-1 removal rate of TR-350 (IM-TR) was about 90% initially, but gradually declined. BRS-350 (BRS) maintained a removal rate of about 45% throughout the experiment. There was no difference in the HMGB-1 removal rate between IM-TR and BRS at 75 minutes, but all other cases showed significant differences. PH respectively. The average value of these three groups showed statistically significant differences at 25 minutes and 50 minutes in HMGB-1 removal capacity. There was no significant difference between IM-TR and BRS (p= 0.54) at 75 minutes.
IM-TR removed the highest amount of total HMGB-1, followed by BRS and IM-PH, which removed the least.
The removal amount of HMGB-1 in each column on average was 142.1 ng/mL for IM-TR, 88.2 ng/mL for BRS, and 20 ng/mL for IM-PH, which was statistically significant Fig. 4 . 
Discussion
In this study, we showed that HMGB-1 is adsorbed by the column which is used in plasma adsorption therapy.
HMGB-1 is a late and lethal mediator in severe sepsis
and it is known to be secreted in two different path- . It is said that endogenous cannabinoids involved in the regulation of cytokine production are directly removed by PMX-DHP leading to an improvement of hemodynamics 27, 29 , but the cytokine cannot be removed by PMX-DHP directly 30 .
HMGB-1 concentration in patients with septic shock strongly correlates with severity of the disease 8 . Although PMX-DHP and CHDF are well-developed blood purification therapies for sepsis in Japan, they are currently controversial as a treatment option. In DIC and multiple organ failure, HMGB-1 levels are significantly increased, which accelerates the chain reactions that lead to cytokine storm. Since PMX-DHP therapy does not directly reduce the amount of HMGB-1, its therapeutic effect on these severe conditions is limited 31 . However, PMX-DHP does adsorb early mediators in sepsis that are upstream of HMGB-1, which eventually decreases the concentration of HMGB-1. Also, many previous studies have reported that high anti-HMGB-1 antibody levels, which inhibit HMGB-1 activity, contribute to an improved survival rate 32 34 .
The IM-TR and IM-PH columns have a carboxyl group which is negatively charged and a hydrophobic group 20, 21 .
HMGB-1, which has two positively charged DNA binding regions, is one of the alarmins which has recently been reported to be related to various diseases 35 37 .
HMGB-1 also has a hydrophobic protein, lysine, in its BRS contains polystyrene as a main material, which is hydrophobic due to the phenyl group. HMGB-1 has a negatively charged region in its C-terminal. Therefore, we hypothesized that HMGB-1 was adsorbed in BRS through both ionic and hydrophobic interactions.
A previously published report showed that it is more reasonable to use charged membranes with adsorption capabilities in order to adsorb HMGB-1 15 . Interestingly our data revealed that hydrophobicity is a more efficient interaction to adsorb HMGB-1 than charge in our columns. We successfully demonstrated that plasma adsorption membranes, especially IM-TR and BRS, were able to adsorb HMGB-1 efficiently for the first time. The limitations of our study include the fact that it was an in vitro experiment lacking in vivo confirmation and controls (e.g.
comparison with PMX-DHP). However, since these plasma adsorption membranes have already been applied for clinical use, especially for autoimmune diseases, they should be equally safe and efficient for the treatment of severe sepsis.
Conclusions
To the best of our knowledge, this is the first study demonstrating HMGB-1 is captured by plasma adsorption.
Control of aberrant HMGB-1 levels by plasma adsorption therapy was successfully observed in the present study, and it can be applied to the treatment of sepsis as a new therapeutic option.
